Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05966090 · ClinicalTrials.gov registry record · Phase 3
A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
A Phase 3 study of Respiratory Syncytial Virus Infections and Respiratory Syncytial Viruses, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 530
- Enrollment target
- 20
- Study locations
NCT05966090: Completed Phase 3 study of Respiratory Syncytial Virus Infections and Respiratory Syncytial Viruses, sponsored by GlaxoSmithKline.
NCT05966090 is a Phase 3 study of Respiratory Syncytial Virus Infections and Respiratory Syncytial Viruses that has completed, run by GlaxoSmithKline. The registered enrollment target is 530 participants, below the 1,066-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05966090, a Phase 3 study of Respiratory Syncytial Virus Infections and Respiratory Syncytial Viruses, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 530 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with HZ/su vaccine and its safety in older adults, aged \>=50 years of age.
Primary Outcome
Anti-gE antibodies were measured with enzyme linked immunosorbent assay (ELISA) and the results were expressed as GMC, in milli international units per milliliter (mIU/mL).
Conditions Studied
Interventions
- BIOLOGICAL RSVPreF3 OA investigational vaccine
- BIOLOGICAL HZ/su vaccine
Study Locations (20)
Quebec
- GSK Investigational Site - Québec
- GSK Investigational Site - Québec
- GSK Investigational Site - Québec
- GSK Investigational Site - Québec
- GSK Investigational Site - Sherbrooke
Ontario
- GSK Investigational Site - Brampton
- GSK Investigational Site - Guelph
- GSK Investigational Site - Toronto
- GSK Investigational Site - Toronto
Florida
- GSK Investigational Site - North Miami Beach
- GSK Investigational Site - West Palm Beach
Texas
- GSK Investigational Site - Fort Worth
- GSK Investigational Site - San Antonio
Alabama
- GSK Investigational Site - Daphne
Arizona
- GSK Investigational Site - Tempe
California
- GSK Investigational Site - Corte Madera
Colorado
- GSK Investigational Site - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2023-07-28 |
| Est. Completion | 2024-07-29 |
| Phase | Phase 3 |
What the finished NCT05966090 record still lists
NCT05966090 is an interventional study that assigns participants to a tested intervention. The registered 530 participants enrollment target is mid-sized for trials with a published cap, below the 1,066-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (50% lower).
The record links to 2 conditions, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 2 interventions - of which RSVPreF3 OA investigational vaccine is the first listed.
NCT05966090 names 20 study sites across 11 states, led by Quebec, Ontario, Florida.
Frequently Asked Questions
What is clinical trial NCT05966090 about?
NCT05966090 is a clinical study titled "A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults". To assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with HZ/su vaccine and its safety in older adults, aged \>=50 years of age.
What is the current status of trial NCT05966090?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 530 participants. The study started on 2023-07-28. Estimated completion is 2024-07-29.
What conditions does trial NCT05966090 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections, Respiratory Syncytial Viruses.
What interventions are being tested in trial NCT05966090?
The interventions under investigation include: RSVPreF3 OA investigational vaccine (BIOLOGICAL), HZ/su vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05966090?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05966090 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05966090's enrollment target sits among peer trials
530 8th of 21 higher than 14 of 21 other Respiratory Syncytial Virus Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Respiratory Syncytial Virus Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
RECRUITING · Phase 3
-
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
ACTIVE NOT RECRUITING · Phase 3
-
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
ACTIVE NOT RECRUITING · Phase 3
-
A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above
COMPLETED · Phase 3
-
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
COMPLETED · Phase 3
-
A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06646276 · 530 participants · Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- NCT06703476 · 530 participants · Phase 3
A Study of Surgical Techniques During Cystectomy
- NCT06880744 · 530 participants · Phase 3
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
- NCT07138040 · 530 participants · NA
Re-Engaging AYA Survivors in Cancer-Related Healthcare
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI